NVCN - Chardan likes PDS Bio in premarket analyst action October, 24 2019 08:56 AM Neovasc Inc. ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Market Perform rating and $44 (5% upside) price target at Oppenheimer.More news on: ACADIA Pharmaceuticals Inc., Nektar Therapeutics, Neovasc Inc., Healthcare stocks news, Stocks on the move, , Read more ...